Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Mylan N.V. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences.

The company started operations in 2002 and began trading as public company in February of 2014. As of December 31, 2019, Revance employed approximately 193 staff members and as of February 14, 2020 had approximately $533 million in cash and investments to fund operations into 2023. Revance's headquarters is located in Newark, California, including office, laboratory and manufacturing space.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

Revance Therapeutics trades on the The NASDAQ Global Market under the ticker symbol “RVNC”.

Revance Therapeutics began trading as public company on February 6, 2014 (NAS:RVNC). A total of 6,900,000 shares (including the underwriters’ overallotment of 900,000 shares) were offered at $16 per share.

The company completed a follow-on offering in June 2014 and issued an additional 4.6 million common shares (including the underwriters' exercised option for 600,000 shares) at $30.50 per share.

In November of 2015, the company completed an additional public offering of 3.7 million shares of its common stock (including the underwriters exercise option for 487,500 shares) at $36.00 per share.

In December of 2017, the company closed an underwritten public offering of 6,139,515 shares of its common stock at a price to the public of $31.00 per share. In the offering, the Company issued and sold 5,389,515 shares, including the exercise in full by the underwriters of their option to purchase 550,806 additional shares of common stock from the Company, and certain stockholders of the Company (the “Selling Stockholders”) sold 750,000 shares, including the exercise in full by the underwriters of their option to purchase 250,000 additional shares of common stock from the Selling Stockholders.

In January 2019, the company completed a public offering of 6,764,705 million shares of its common stock (including the underwriters excised option for 882,352 shares) at $17.00 per share.

In January 2020, Revance closed a underwritten public offering of 7,475,000 shares of its common stock at a price to the public of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase 975,000 shares.

In February 2020, Revance closed a offering of $287.5 million aggregate principal amount of convertible senior notes due 2027 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Following this financing and the close of the stock offering in January, as of February 14, Revance had $533.3 million in cash, cash equivalents and short-term investments on a preliminary basis.

The Company’s headquarters is located in Newark, California.  Our principal offices are located at 7555 Gateway Boulevard Newark, California 94560.  The phone number is (510) 742-3400.

The biographies of Revance Therapeutics’ directors are available in the “Board of Directors” section of our company website here.

The biographies of Revance Therapeutics’ management are available in the “Management Team” section of our company website here.

As of February 13, 2020, Revance Therapeutics had a total common shares outstanding of 56.9 million.

As of December 31, 2019, Revance Therapeutics held approximately 41 issued patents and approximately 124 pending patent applications in several countries.

Revance Therapeutics’ fiscal year ends December 31st.

Revance Therapeutics’ independent auditor is PricewaterhouseCoopers LLP.

Address: 488 S Almaden Blvd
#1800, San Jose, California, 95110
Phone: (408) 817-3700

Revance Therapeutics’ outside legal counsel is Cooley LLP.

Address: 3175 Hanover Street Palo Alto, California, 94304

Phone: (650) 843-5000

No, Revance Therapeutics does not pay a dividend at this time.

No, Revance Therapeutics does not offer a direct stock purchase program.

Revance Therapeutics’ quarterly and annual reports and other SEC filings are available by selecting the “Financial Information” section of our “Investors” page on our website here, or through SEC’s website here.

Revance will hold its 2020 Annual Meeting of Stockholders on May 14, 2020. Due to COVID-19 and social distancing, it will be a virtually-only meeting. See your proxy materials for details on how to access the meeting.

Computershare
USA
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
web.queries@computershare.com

Shareholder Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY  40233

Shareholder Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Please see the "Events & Presentations" section of our website for a listing of upcoming earnings announcements and other key events here.

You can contact Revance Therapeutics’ Investor Relations via email by clicking here.

The Company was incorporated in the state of Delaware in August 1999 under the name Essentia Biosystems, Inc.  It commenced operations in June 2002 and, in April 2005, changed its name to Revance Therapeutics, Inc.

If your shares are held in street name (by your broker), you must notify the securities firm holding your stock.  If you hold stock certificates in your own name, address changes should be submitted in writing via U.S. mail to our transfer agent, Computershare:

For written requests by regular mail:
Computershare
P.O. Box 30170
College Station, TX, 77842
USA

For written requests by overnight delivery:
Computershare
211 Quality Circle, Suite 210
College Station, TX, 77845
USA

If you hold stock certificates in your own name, please contact our transfer agent, Computershare, regarding the replacement of lost certificates:

For telephone inquiries:
+1 (877) 373 6374 (US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)

For requests by email:
web.queries@computershare.com

For written requests by regular mail:
Computershare
P.O. Box 30170
College Station, TX, 77842
USA

For written requests by overnight delivery:
Computershare
211 Quality Circle, Suite 210
College Station, TX, 77845
USA

As of December 31, 2019, Revance Therapeutics had 193 full-time employees.

NASDAQ Composite Index
Russell 2000 Index
Nasdaq Biotechnology Index
Russell 3000 Index
Russell 2000 Growth Index
Russell 2500 Index
Russell 3000 Growth Index
Russell 2500 Growth Index
Russell 2000 Health Care Index
Russell 2000 Biotechnology Index
Bloomberg ESG Data Index
S&P Total Market Index
S&P Pharmaceuticals Select Industry Index
Russell 3000 Health Care Index
S&P Global BMI (US Dollar)
Russell 2000 Health Care Growth Index
NASDAQ Health Care Index
Russell 2500 Health Care Growth Index
NASDAQ US Benchmark Index
SSGA Total Stock Market Total Return Index
Russell Global Index
S&P Developed BMI (US Dollar)
NASDAQ US Small Cap Index
Russell Global excluding Japan Index
Russell 2000 Biotechnology Growth Index
S&P United States BMI (US Dollar)
Russell 3000 Biotechnology Index
Russell Small Cap Completeness Index
Solactive US Broad Market Index (GTR)
S&P Global Mid Small Cap Index
Russell Global excluding Canada Small Cap Index
Russell Global Small Cap Index
R2500GBiotec
Russell Global Developed Index
Invesco FTSE RAFI US 1500 Small-Mid ETF INAV Index
Russell 3000 Health Care Growth Index
NASDAQ US All Market Index
SSGA Small-Cap Total Return Index
Russell 1000 Net Return- CAD
MSCI USA IMI ESG Leaders Index
Russell 2000 Momentum Factor Total Return Index
S&P Global SmallCap (US Dollar)
CRSP US Total Market Index CAD-hedged
R2500G Pharm&BiotcSubSec
Russell 2500 Health Care Index
S&P Developed SmallCap (US Dollar)
Invesco Russell 2000 Equal Weight ETF INAV Index
Russ Global SC Growth
S&P North America BMI (US Dollar)
Nasdaq US 700 Small Cap Growth Index
MSCI USA Select Factor Mix Price Return USD Index
SSGA Total Stock Market Index
SSGA Small-Cap Index
Fidelity U.S. Total Investable Market Index PR
Russell 2000 Size Factor Total Return Index
MSCI USA Broad ESG Leaders Index
Russell Small Cap Completeness Growth Index
S&P Global BMI Health Care USD PR Index
Invesco Russell 2000 Pure Growth ETF INAV Index
S&P Global BMI Between USD1 Billion and USD5 Billion in USD Index
NASDAQ US 1500 Index
MSCI USA IMI (VRS Taxes) Net Return USD Index
MSCI USA Small Cap ESG Leaders Index
Russell RSCC Health Care Index
Russell RSCC Health Care Growth Index
Bloomberg State Index of California
S&P United States SmallCap (US Dollar)
Nasdaq US Multi Cap Growth Index
Fidelity U.S. Extended Investable Market Index PR
Invesco PureBetaSM MSCI USA Small Cap ETF INAV Index
S&P United States SC Val
S&P Global BMI Value USD Index
SPGlblBMI PharBioLifeSci
MSCI USA SMID ESG Leaders Index
S&P North America SmallCap (US Dollar)
Russ GLO Healthcare
Russell Global excluding Japan Small Cap Index
Russell Global Growth Index
Russell Global Developed Small Cap Index
Russell Global Developed excluding Japan Index
Russell Global Developed excluding Japan Small Cap Index
Russell Global excluding United Kingdom Index
Russell Global excluding Australia Index
Russell Global excluding United Kingdom Small Cap Index
Russell Global excluding Australia Small Cap Index
Russell Global excluding Canada Index
Russ Developed xUK
Russ North America
Nasdaq US Hlthcare Innovators TR
Bloomberg U.S. Equity Index
S&P Developed SmallCap (US Dollar) Total Return
Russell Microcap Index